Futura Medical PLC (AIM:FUM, OTC:FAMDF) surged in Monday’s early trades following a bullish announcement regarding its MED3000 topical, gel-based erectile dysfunction treatment.
The group has entered into a licensing agreement with world-leading consumer health company Haleon PLC (LSE:HLN, NYSE:HLN) for the exclusive US commercialisation rights to MED3000.
Futura shares had added over 11% to hit 57.4p by 9.15am.